US Bancorp
AXSM icon

US Bancorp’s Axsome Therapeutics AXSM Stock Holding History

US Bancorp’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.3M Sell
66,580
-64,834
-49% -$14.1M 0.02% 346
2026
Q1 		$22.2M Buy
131,414
+429
+0.3% +$74.1K 0.03% 291
2025
Q4 		$23.9M Sell
130,985
-548
-0.4% -$76.5K 0.03% 297
2025
Q3 		$16M Buy
131,533
+686
+0.5% +$77.3K 0.02% 359
2025
Q2 		$13.7M Buy
130,847
+552
+0.4% +$58.5K 0.02% 384
2025
Q1 		$15.2M Sell
130,295
-724
-0.6% -$82.5K 0.02% 365
2024
Q4 		$11.1M Sell
131,019
-2,107
-2% -$194K 0.01% 416
2024
Q3 		$12M Buy
133,126
+421
+0.3% +$36.7K 0.02% 400
2024
Q2 		$10.7M Sell
132,705
-800
-0.6% -$59.2K 0.01% 408
2024
Q1 		$10.7M Sell
133,505
-9,919
-7% -$833K 0.01% 415
2023
Q4 		$11.4M Buy
143,424
+4,653
+3% +$311K 0.02% 395
2023
Q3 		$9.7M Sell
138,771
-961
-0.7% -$71.8K 0.02% 403
2023
Q2 		$10M Buy
139,732
+4,241
+3% +$313K 0.02% 407
2023
Q1 		$8.36M Sell
135,491
-3,301
-2% -$217K 0.01% 440
2022
Q4 		$10.7M Sell
138,792
-11,614
-8% -$694K 0.02% 389
2022
Q3 		$6.71M Sell
150,406
-112,476
-43% -$5.62M 0.01% 454
2022
Q2 		$10.1M Buy
262,882
+260,944
+13,465% +$8.25M 0.02% 380
2022
Q1 		$80K Sell
1,938
-8,938
-82% -$277K ﹤0.01% 2377
2021
Q4 		$411K Sell
10,876
-224
-2% -$8.24K ﹤0.01% 1623
2021
Q3 		$366K Buy
11,100
+1,590
+17% +$62K ﹤0.01% 1673
2021
Q2 		$641K Buy
9,510
+136
+1% +$8.16K ﹤0.01% 1419
2021
Q1 		$531K Buy
9,374
+313
+3% +$22K ﹤0.01% 1465
2020
Q4 		$738K Buy
9,061
+630
+7% +$47.1K ﹤0.01% 1244
2020
Q3 		$601K Buy
8,431
+5,678
+206% +$442K ﹤0.01% 1232
2020
Q2 		$226K Sell
2,753
-351
-11% -$27K ﹤0.01% 1690
2020
Q1 		$183K Buy
3,104
+1,258
+68% +$103K ﹤0.01% 1706
2019
Q4 		$191K Buy
1,846
+653
+55% +$26.4K ﹤0.01% 1854
2019
Q3 		$25K Buy
1,193
+371
+45% +$9.53K ﹤0.01% 2745
2019
Q2 		$21K Buy
+822
New +$16.5K ﹤0.01% 2852

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

US Bancorp's AXSM Position: Q2 2026 in Review

US Bancorp reduced its Axsome Therapeutics (AXSM) stake by 49% in Q2 2026, selling an estimated $14.1M and leaving 66,580 shares worth $16.3M. The position accounts for 0.02% of the portfolio, ranked #346.

US Bancorp first reported a position in AXSM in Q2 2019 and has held it in 29 quarters since. The position peaked at $23.9M in Q4 2025. 505 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • US Bancorp held 66,580 shares of Axsome Therapeutics worth $16.3M as of Q2 2026.
  • US Bancorp sold 64,834 Axsome Therapeutics shares in Q2 2026, an estimated $14.1M.
  • Axsome Therapeutics made up 0.02% of US Bancorp's portfolio in Q2 2026, its #346 holding.
  • US Bancorp first reported a position in Axsome Therapeutics in Q2 2019 and has held it in 29 quarters since.
  • US Bancorp's Axsome Therapeutics position peaked at $23.9M in Q4 2025.
  • 505 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.